Research programme: indomethacin/phosphatidylcholine - PLx Pharma/UTHealth
Alternative Names: Phosphatidylcholine-enriched indomethacinLatest Information Update: 18 Jul 2024
At a glance
- Originator University of Texas Health Science Center at Houston
- Developer PLx Pharma; University of Texas Health Science Center at Houston
- Class Analgesics; Antirheumatics; Chlorobenzenes; Indoles; Nonsteroidal anti-inflammatories; Phospholipids; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Congenital heart defects
Most Recent Events
- 14 Sep 2023 Discontinued for Congenital heart defects in USA (unspecified route)
- 30 Mar 2012 Investigation in Congenital heart disorders in USA (unspecified route)